Physician profile
Anthony Esposito
NPI 1083655187
$80,994.46
in general payments reported to CMS, 2019-2025
60 companies · $7,724 in 2025
The $7,724 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,697 · 2020: $17K · 2021: $16K · 2022: $19K · 2023: $10K · 2024: $8,554 · 2025: $7,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $8,761 · Consulting Fee: $1,800 · Travel and Lodging: $207 · Education: $33.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,787.50 |
| Food and Beverage | $8,760.62 |
| Consulting Fee | $1,800.00 |
| Travel and Lodging | $206.79 |
| Education | $33.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44,394.74 | 2021-2025 | |
| Allergan, INC. | $14,733.04 | 2019-2022 | |
| Sk Life Science, INC. | $3,209.94 | 2020-2025 | Xcopri |
| Emd Serono, INC. | $2,692.03 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $2,665.18 | 2019-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,418.30 | 2019-2025 | |
| Biogen, INC. | $1,220.54 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $953.46 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Csl Behring | $942.41 | 2020-2025 | Hizentra |
| Lundbeck LLC | $648.51 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $601.71 | 2019-2024 | Qelbree |
| Lilly USA, LLC | $521.50 | 2019-2025 | Amyvid, Kisunla |
| Amgen INC. | $403.38 | 2019-2025 | Uplizna, Aimovig |
| Neurelis, INC. | $379.33 | 2020-2025 | Valtoco |
| Argenx US, INC. | $377.01 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.